Conflicts of Interest in GLP-1 Research: What a Disclosure Means

A conflict-of-interest disclosure in GLP-1 research tells you who paid for a study and what financial ties the authors have, such as consulting fees, grants or company stock. It doesn't mean the results are wrong, and the absence of one doesn't mean they're right. It's context that tells you which parts of a study deserve a closer look.

Here's the plot twist most readers don't expect: nearly every landmark GLP-1 trial was funded by the company that makes the drug. That's how drug development works in the US. So the useful question is never "was it industry-funded?" It's "what else should I check, given that it was?"

Who funded the big GLP-1 trials?

Straight from the papers' own funding lines:

Trial	Drug	Funded by
STEP 1	Semaglutide 2.4 mg	Novo Nordisk
SELECT	Semaglutide 2.4 mg	Novo Nordisk
SURMOUNT-1	Tirzepatide	Eli Lilly
SURMOUNT-5 (tirzepatide vs semaglutide)	Both	Eli Lilly
ATTAIN-1	Orforglipron	Eli Lilly

Phase 3 trials with thousands of participants cost enormous sums, and companies run them because regulators need that evidence for approval. Industry funding is the default, not a scandal.

Does industry funding change results?

On average, there's evidence it can. A Cochrane review of 75 studies on this question found that industry-sponsored drug and device studies:

• more often had favorable efficacy results (risk ratio 1.27),
• more often had favorable conclusions (risk ratio 1.34),
• and showed less agreement between their results and their conclusions than non-industry studies.

Here's the interesting part: the review did not find these studies scored worse on standard bias checks like randomization or allocation concealment. Industry studies more often had low risk of bias from blinding. The authors concluded there's an "industry bias that cannot be explained by standard 'Risk of bias' assessments."

In plain words: the bias usually isn't in the obvious mechanics. It can sit in which questions get asked, which comparator is picked, which outcomes get headlined, and how conclusions are worded.

Spot the trick

1. "The head-to-head trial was funded by the winning drug's maker, so it's rigged."

Show answer

SURMOUNT-5, which found tirzepatide −20.2% vs semaglutide −13.7%, was funded by Lilly, tirzepatide's maker. That's worth noting. But it was randomized, its main outcome (measured weight) is hard to fudge, and it was published in a peer-reviewed journal with a registered design. The funding is a reason to check details, like the doses used and that it was open-label, not a reason to throw it out.

2. "This study was independent, so it's trustworthy."

Show answer

Independent funding removes one kind of conflict, not all problems. A small, poorly designed academic study can be far less reliable than a large, well-run industry trial. Judge the design too.

3. "The conclusion says the drug is 'highly effective and well tolerated.'"

Show answer

Conclusions are the most spin-prone part of any paper. Read the results table instead: how many stopped because of side effects, how big the difference was, how long it lasted. The Cochrane review found industry studies' conclusions matched their results less often.

Scoring: 3 out of 3 means you can read a funding line without either panicking or shrugging. That's the goal.

What does a good disclosure include?

The International Committee of Medical Journal Editors (ICMJE), whose recommendations many medical journals follow, asks papers to report:

• Sources of support, with sponsor names.
• The sponsor's role in study design, data collection, analysis, writing and the decision to publish, or a statement that it had none.
• Whether the authors had access to the study data, and how much.
• Each author's relationships: employment, consulting, stock or options, honoraria, patents, paid testimony and more.

ICMJE also notes that "perceptions of conflict of interest are as important as actual conflicts of interest." That's why disclosures matter even when everyone acted in good faith.

Where do you find disclosures in a GLP-1 paper?

Look in these places:

1. The end of the abstract. NEJM-style abstracts often end with "(Funded by…; ClinicalTrials.gov number…)."
2. "Funding" or "Role of the funder" section. Says who designed, analyzed and wrote.
3. Author disclosure forms. Often linked as supplementary files.
4. Author affiliations. Company employees are listed with the company's name.

Then ask:

Question	Why it matters
Did the sponsor design the trial and analyze the data?	More control means more need for independent checks
Did academic authors have full data access?	Signals whether outsiders could verify analyses
Was the trial registered before it started?	Prevents switching outcomes after seeing results
Did the headline outcome match the registered primary outcome?	Spot outcome switching
Has anyone independent confirmed it?	Replication beats reassurance

You can check registration and primary outcomes on ClinicalTrials.gov using the NCT number. Our guide to checking whether a claim is peer-reviewed shows how.

Can you check whether your own doctor gets industry payments?

Yes. The federal Open Payments program, run by CMS, requires drug and device companies to report payments and other transfers of value to covered recipients such as physicians. You can search by name at openpaymentsdata.cms.gov. For Program Year 2025, CMS published 17.07 million records totaling $14.67 billion.

A payment record doesn't mean your doctor's advice is biased. It might be for a research grant, consulting, a speaking event or a meal. But it's public information, and it's fair to ask about it respectfully if it worries you.

For people who aren't researchers or doctors, like influencers paid to talk about GLP-1s, the rules are different. See our sibling post on evaluating a medical influencer's sponsorship disclosure.

How should you weigh it all?

A simple mental model:

• Strong design + industry funding (like STEP 1 or SELECT): take the main, prespecified results seriously; be more skeptical of exploratory analyses and glowing conclusions.
• Weak design + any funding: be skeptical regardless.
• Results confirmed by other teams or other designs: more confidence.

Then run the numbers through our five-minute headline routine. And if a study changes how you think about your own treatment, bring it to your prescriber or pharmacist before acting on it.

Common questions

Were the semaglutide and tirzepatide trials funded by drug companies?

Yes. STEP 1 and SELECT were funded by Novo Nordisk; SURMOUNT-1 and SURMOUNT-5 by Eli Lilly. This is standard for phase 3 drug trials.

Does industry funding mean a study is biased?

Not necessarily, but a Cochrane review found that industry-sponsored studies more often report favorable results and conclusions. Check the design, the registered outcomes and whether others have confirmed the findings.

What is a conflict of interest disclosure?

It's a statement in a paper listing funding sources and authors' financial or professional ties, such as employment, consulting, stock or grants, that could affect, or be seen to affect, their work.

How can I look up payments to my doctor from drug companies?

Search the CMS Open Payments database at openpaymentsdata.cms.gov by your doctor's name. It lists payments and transfers of value reported by manufacturers.